Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Rilvegostomig in Metastatic Solid Tumor: NCT07115043 Clinical Landscape Report 2026
28 September 2026
NCT07115043 clinical landscape for Metastatic Solid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Trastuzumab Rezetecan in PD-L1 positive Triple Negative Breast Cancer: NCT07111832 Clinical Landscape Report 2026
28 September 2026
NCT07111832 clinical landscape for PD-L1 positive Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Humanized CD70-Targeted CAR-T Cell Incorporating TLR2(Tongji Hospital) in Advanced Renal Cell Carcinoma: NCT07113977 Clinical Landscape Report 2026
28 September 2026
NCT07113977 clinical landscape for Advanced Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Palbociclib in Metastatic Renal Cell Carcinoma: NCT07123090 Clinical Landscape Report 2026
28 September 2026
NCT07123090 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludeoxyglucose F-18 in Sarcoma: NCT07118176 Clinical Landscape Report 2026
28 September 2026
NCT07118176 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Large B-cell lymphoma: NCT07126236 Clinical Landscape Report 2026
28 September 2026
NCT07126236 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sirolimus in Kaposiform Hemangioendothelioma: NCT07131644 Clinical Landscape Report 2026
28 September 2026
NCT07131644 clinical landscape for Kaposiform Hemangioendothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Doxorubicin Hydrochloride in Leiomyosarcoma: NCT07125183 Clinical Landscape Report 2026
28 September 2026
NCT07125183 clinical landscape for Leiomyosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LTZ-301 in Follicular Lymphoma: NCT07121946 Clinical Landscape Report 2026
28 September 2026
NCT07121946 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in Diffuse Large B-Cell Lymphoma: NCT07124936 Clinical Landscape Report 2026
28 September 2026
NCT07124936 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Polatuzumab Vedotin-Piiq in Diffuse large B-cell lymphoma recurrent: NCT07122609 Clinical Landscape Report 2026
28 September 2026
NCT07122609 clinical landscape for Diffuse large B-cell lymphoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Ipilimumab in Metastatic Renal Cell Carcinoma: NCT07128680 Clinical Landscape Report 2026
28 September 2026
NCT07128680 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.